

NMIMR-SCIENTIFIC AND TECHNICAL COMMITTEE
Reviewer's Checklist for Research Protocols

STC Paper # _____ Title: _____

1. INTRODUCTION, SPECIFIC AIMS AND RATIONALE

YES

NO

N/A

- a. Are the specific aims clearly specified? _____
- b. Are there adequate preliminary data to justify the research? _____
- c. Is there appropriate justification for the research? _____

Comments:

2. SCIENTIFIC DESIGN

YES

NO

N/A

- a. Is the scientific design adequate to answer the question? _____
- b. Are the objectives achievable within a given time period? _____
- c. Is the scientific design (i.e. randomization; placebo controls; Phase 1, 2, or 3) described and adequately justified? _____

Comments:

3. INCLUSION/EXCLUSION CRITERIA

YES

NO

N/A

- a. Are inclusion and exclusion criteria clearly specified? _____
- b. If women or children are included or excluded is this justified? _____
- c. Is the choice of research participants appropriate for the questions being asked? _____

Comments:

4. RECRUITMENT OF PARTICIPANTS

YES NO N/A

- a. Are the methods for recruiting potential participants well defined? _____
- b. Are the location and timing of the recruitment process acceptable? _____
- c. Is the individual performing the recruitment appropriate for the process? _____
- d. Are all recruitment materials submitted and appropriate? _____
- e. Are there acceptable methods for screening participants before recruitment? _____

Comments:

5. RESEARCH PROCEDURES

YES NO N/A

- a. Are the rationale and study procedures accurately described and acceptable? _____
- b. Is there a clear differentiation between research procedure and standard of care? _____
- c. Are the individuals performing the procedures appropriately trained? _____
- d. Are there adequate plans to inform participants about research results? _____

Comments:

6. DRUG, BIOLOGIC AND DEVICES

YES NO N/A

- a. Is the status of the drug described and appropriate
(new use of a Ghana FDA-approved drug, or an FDA-approved
drug within approved indications)? _____
- b. Are the drug dosage and route of administration appropriate? _____
- c. Are the drug or device safety and efficacy data sufficient to
warrant the proposed phase of testing? _____
- d. Is the significant risk or non-significant risk status of the
devised described and appropriate? _____

Comments:

7. DATA ANALYSIS

- | | YES | NO | N/A |
|--|------------|-----------|------------|
| a. Is the rationale for the proposed number of participants reasonable? | _____ | _____ | _____ |
| b. Are the plans for data and statistical analysis well defined and justified, including the use or stopping rule endpoints? | _____ | _____ | _____ |
| c. Are there adequate provisions for monitoring data (DSMB)? | _____ | _____ | _____ |

8. REFERENCES

- | | YES | NO |
|-----------------------------------|------------|-----------|
| a. Are there adequate references? | _____ | _____ |

Comments:

9. ANY OTHER COMMENT

Recommendation: a) approve _____ b) disapprove _____ c) defer _____

Reviewer's Name and Signature: _____ **Date:** _____